Author/Authors :
El-Zimaity, Maha M. Ain Shams University - Department of Clinical Hematology and Bone Marrow Transplantation, Egypt , Hassan, Essam A. Ain Shams University - Department of Clinical Hematology and Bone Marrow Transplantation, Egypt , Abd El-Wahab, Soha E. Ain Shams University - Department of Clinical Pathology, Egypt , Abd El-Ghaffar, Afaf A. Ain Shams University - Department of Clinical Pathology, Egypt , Mahmoud, Nazek A. Ain Shams University - Department of Clinical Pathology, Egypt , Elafifi, Amal M. Ain Shams University - Department of Clinical Hematology and Bone Marrow Transplantation, Egypt , Moussa, Mohamed M. Ain Shams University - Department of Clinical Hematology and Bone Marrow Transplantation, Egypt , El-Gohary, Ghada M. Ain Shams University - Department of Clinical Hematology and Bone Marrow Transplantation, Egypt , Hagras, Mona M. Ain Shams University - Department of Clinical Pathology, Egypt , Mowafy, Nadia M. Ain Shams University - Department of Clinical Pathology, Egypt
Abstract :
Objectives: To describe the experience in setting up a bone marrow transplant program at Ain Shams University, Cairo, Egypt. Methods: Sixteen patients were transplanted at Ain Shams University Bone Marrow Transplantation unit from March 2005 to January 2008. Results: Sixteen patients were transplanted with a median age of 25 years. Indications for transplantation were chronic myeloid leukemia, acute myeloid leukemia, aplastic anemia, acute lymphoblastic leukemia, and aggressive lymphoma. Seven donors and 6 patients were positive for cytomegalovirus immunoglobulin G (IgG) antibody (Ab) pretransplant. Only one patient was positive for toxoplasma IgG Ab and another had a high titre for toxoplasma IgM Ab pretransplant. Two donors and 2 recipients were positive for hepatitis B antibody markers; however, none were positive for hepatitis B virus DNA by polymerase chain reaction (PCR). None of the patients or donors were positive for hepatitis C virus via PCR pre-transplant. Acute graft versus host disease (GVHD) was seen in 3 patients, while chronic GVHD was seen in 5 patients. Primary cause of death was recurrence in 2 patients and graft failure in one patient. Thirteen are alive and disease free with a median follow-up of 20 months. Conclusion: Although our unit is a relatively new unit, these results are comparable to those achieved in the Western world and cost a mean of US$250,000.
